New Advances in Iron Chelation Therapy
Open Access
- 1 January 2006
- journal article
- review article
- Published by American Society of Hematology in Hematology-American Society Hematology Education Program
- Vol. 2006 (1), 42-47
- https://doi.org/10.1182/asheducation-2006.1.42
Abstract
The emergence of new chelators is likely to have a major impact on the treatment of thalassemia major, sickle cell disease and other hematologic disorders for which regular red cell transfusions are required either to correct severe anemia or to prevent major complications of the underlying disease. In comparison with deferoxamine, which requires prolonged parenteral infusion to achieve negative iron balance, orally active chelators offer the promise of easier administration and better compliance. Moreover, the availability of more than one iron chelator opens up the possibility of combination therapy to target iron in specific organs and to enhance overall iron excretion. Long-term studies, employing new technologies to measure tissue iron, are required to determine whether the new chelators will be as safe and effective as deferoxamine in maintaining control of iron stores and preventing iron-induced cardiac disease, the major complication of transfusional iron overload.Keywords
This publication has 24 references indexed in Scilit:
- Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonanceBritish Journal of Haematology, 2004
- Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia majorBlood, 2004
- Role of deferiprone in chelation therapy for transfusional iron overloadBlood, 2003
- Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemiaBlood, 2000
- Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia MajorNew England Journal of Medicine, 1998
- Results of Long-Term Iron-Chelating TherapyActa Haematologica, 1996
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Iron-balance and dose-response studies of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell diseaseBlood, 1994
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992
- Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patientsThe Lancet, 1990